Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
P/E(ttm) 22.56
IHE's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 22.56 )
Ranked among companies with meaningful P/E(ttm) only.
IHE' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.97
Current: 22.56
0
30.97
PE(NRI) 22.56
IHE's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 22.56 )
Ranked among companies with meaningful PE(NRI) only.
IHE' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.97
Current: 22.56
0
30.97
P/B 2.49
IHE's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 2.49 )
Ranked among companies with meaningful P/B only.
IHE' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.23
Current: 2.49
0
3.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.91
IHE's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 0.91 )
Ranked among companies with meaningful Dividend Yield only.
IHE' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.1
Current: 0.91
0
1.1
Yield on cost (5-Year) 0.91
IHE's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 0.91 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IHE' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.1
Current: 0.91
0
1.1

More Statistics

Short Percentage of Float0.00%
52-Week Range $129.41 - 156.52
Shares Outstanding (Mil)5,100,000.00
» More Articles for IHE

Headlines

Articles On GuruFocus.com
4 Stocks Reach Their 3-Year Lows Jan 21 2017 
A Fond Farewell Jan 21 2017 
Insider Buys Highlight for the Week of Jan. 20 Jan 21 2017 
US Market Indexes Lower for the Week Jan 21 2017 
John Rogers Comments on JLL Jan 20 2017 
John Rogers Comments on Charles River Laboratories Intl Jan 20 2017 
John Rogers Comments on Keysight Technologies Jan 20 2017 
John Rogers Comments on Thermo Fisher Scientific Inc. Jan 20 2017 
John Rogers Comments on Zimmer Biomet Holdings Jan 20 2017 
John Rogers Comments on Northern Trust Corp Jan 20 2017 

More From Other Websites
How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16? Jan 20 2017
What Lies Ahead for Pharma ETFs? Jan 19 2017
Biotech ETFs: When Will The Pain End? Jan 17 2017
Mylan’s Recent Commercial and Product Developments Jan 13 2017
Biotech ETFs Continue To Bleed Jan 12 2017
Mylan’s EpiPen Controversy: Is It a Brand or a Generic? Jan 11 2017
Biotech, Pharma ETFs Sink; Trump Promises "Bidding Procedures" Jan 11 2017
Top 5 Pharmaceutical ETFs for 2016 Dec 21 2016
Horizon Pharma’s Orphan Drug Segment: 3Q16 Performance Dec 20 2016
Trending: Transportation and Steel Industries Prepare for Trumponomics Dec 15 2016
Exploring Avelumab’s Opportunities in the PD-1/PD-L1 Space Dec 13 2016
Johnson & Johnson’s Consumer Segment in 3Q16 Dec 12 2016
How Did Pfizer’s Innovative Health Business Perform in 3Q16? Dec 12 2016
Johnson & Johnson’s Business Segment Performance in 3Q16 Dec 09 2016
Two Nano-Cap Pharma Stocks To Watch Right Now Dec 02 2016
Pfizer Divests Hospira’s Infusion System Business to ICU Medical Nov 29 2016
Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios Nov 17 2016
Analyzing Future Estimates for Johnson & Johnson Oct 25 2016
Pfizer’s Divestment of Hospira Infusion Systems Oct 14 2016
Medicare Negotiations Would Lead to Huge Cost Savings Oct 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK